AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05072899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: platelet rich plasm
Description: local injection of shoulder joint by platelet rich plasm
Study NCT05072899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: local injection of shoulder joint by Hyaluronic acid
Study NCT02103465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: transdermal patch
Study NCT03401073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Description: Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.
Study NCT02103465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: transdermal patch
Study NCT02118610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-tetrahydropalmatine (30mg)
Description: Active comparator
Study NCT02118610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Placebo
Study NCT04208763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem
Description: Inj Imipenem 1gm i.v. TDS
Study NCT04208763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: Inj Imipenem 1gm i.v. TDS
Study NCT04208763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tigecycline
Description: Inj Tigecycline 100mg stat f/b 50mg i.v. OD
Study NCT06143189 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hosting conditions
Description: Hosting conditions care~the patients are welcome by the nurse, whom talk and give the comfort needed by the patients before starting the treatments.
Study NCT06143189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hosting conditions
Description: Hosting conditions care~the patients are welcome by the nurse, whom talk and give the comfort needed by the patients before starting the treatments.
Study NCT06143189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital Clowns
Description: The HCs Palhaços D'Opital (PdO) have a program aiming to bring joy, affection and good mood to adults and elders in hospital environment. They work in pairs, dressed in colorful costumes and they prepared sketches in advance. Their performances recreate day-to-day situations (e.g., clowns trying to install a new TV screen; planning a wedding between the clowns and asking the public for their ideas), ending with specific closure, in order to indicate to the audience that the session had finished and to promote a positive environment after their departure. Each intervention lasted around 15 minutes.
Study NCT04208763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: Inj Tigecycline 100mg stat f/b 50mg i.v. OD
Study NCT04208763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMCSF
Description: Inj GM-CSF 500mcg s.c. OD
Study NCT04208763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: Inj Colistin 9 MIU i.v. stat f/b 4.5 MIU i.v. BD
Study NCT04208763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: Inj Colistin 9 MIU i.v. stat f/b 4.5 MIU i.v. BD
Study NCT00621855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matched placebo
Study NCT00621855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: capsules, twice daily, 26 weeks treatment
Study NCT01240057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fetal endoluminal tracheal occlusion
Description: percutaneous fetoscopy, positioning of endoluminal balloon at 27-30 weeks and whenever possible elective removal at 34 weeks
Study NCT01240057 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: watchful waiting during pregnancy
Description: pregnancy surveillance for fetal wellbeing, development of polyhydramnios and cervical shortening
Study NCT04586114 — intervention group
Intervention type: DRUG
Intervention: Corticosteroids and Derivatives
Description: Any systemic corticosteroid treatment administrated during ICU stay
Study NCT01269372 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PillCam Colon 2
Description: Each subject will be required to follow a bowel preparation regimen and will undergo Capsule Endoscopy (CE).~Following capsule ingestion and depending on capsule progression through the digestive tract subjects will be required to take an additional volume of laxatives in order to enhance capsule propulsion and maintain adequate cleansing of the colon.
Study NCT01269372 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Colonoscopy
Description: The colonoscopy procedure will be scheduled approximately 4-6 weeks after the CE procedure, and the colonoscopy bowel preparation will be the same as the bowel preparation for CE.
Study NCT04093518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: 2 transdermal patches to be changed twice a week for the duration of 16 weeks
Study NCT04093518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 transdermal patches to be changed twice a week for the duration of 16 weeks
Study NCT03401073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
Study NCT03060850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC0010MA
Description: Participants in the dose escalation cohorts will be treated with AC0010MA every 28 days
Study NCT01719887 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Conservative treatment with functional brace.
Study NCT01719887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operative treatment
Description: Operative treatment with open reduction and internal fixation using 4,5mm locking compression plate.
Study NCT00657943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: insulin detemir
Description: insulin as requested
Study NCT01473810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vacc-4x low dose
Description: 80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
Study NCT01473810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vacc-4x medium dose
Description: 400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
Study NCT01473810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vacc-4x high dose
Description: 1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
Study NCT01473810 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Zero dose
Description: 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
Study NCT00657943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart + insulin aspart protamin
Description: insulin as requested
Study NCT00657943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: insulin aspart + insulin aspart protamin
Description: insulin as requested
Study NCT00657943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: insulin as requested
Study NCT00657943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin aspart
Description: insulin as requested
Study NCT01924975 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saphenous vein cannulation
Description: Intravenous cannulation to saphenous vein
Study NCT01719887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy is arranged to both groups at 3 and 9 wks.
Study NCT01719887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy is arranged to both groups at 3 and 9 wks.
Study NCT01046630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765
Description: single infusion
Study NCT01046630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: single infusion
Study NCT01046630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single infusion
Study NCT03532230 — intervention group
Intervention type: PROCEDURE
Intervention: Osteopathic Manipulative Treatment (OMT)
Description: No specific OMT techniques will be required for the present study. However, data on the number of OMT sessions patients receive will be collected.
Study NCT01223235 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
Description: A maximum of 6 doses of the polyvalent-KLH vaccine and OPT-821 will be administered to each patient as per the schedule. Bevacizumab will be administered once every two weeks until week 11 and then once every three weeks according to the schedule. When the 6 vaccinations of the polyvalent-KLH vaccine +OPT821 are completed, patients may still continue to receive bevacizumab on the once every three week schedule.
Study NCT01529658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal hypothermia
Description: Within 10 seconds of clamping the renal vessels, the kidney will be encased with saline ice slush for a period of 10 minutes. The slush will be created from sterile saline using an operating room slush machine. The slush is applied by the surgeon and lightly packed around the kidney to ensure complete coverage with at least a 2 cm layer. Slush removal is performed by the surgeon beginning at the 10 minute mark. Enough slush is removed to uncover the tumour area. Surgical incision of the kidney begins as soon as the tumour area is uncovered.~When reconstruction of the kidney is complete, the slush is completely removed from the surgical field and the clamps are removed from the renal vein and artery.
Study NCT03851588 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is not given with a supplementary dose of dolutegravir 50 mg.
Study NCT03851588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir 50 mg
Description: Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is given with a supplementary dose of dolutegravir 50 mg.
Study NCT01924975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound with a linear transducer (L15-7io)
Description: Portable, bed-side ultrasound to detect saphenous vein
Study NCT01924975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A 22 or 24 G intravenous catheter
Study NCT02587130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: ketamine administered in bolus by subcutaneous injection
Study NCT00401323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel (XRP6976)
Study NCT00401323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Study NCT00401323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00401323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil (5-FU)
Study NCT00401323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Study NCT01030211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet transfusion
Description: 4 units of platelets for patients with platelet count \<20x10\^3/uL
Study NCT01030211 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Supportive care
Description: Supportive care includes symptomatic treatment, fluid therapy and monitoring of full blood count and blood pressure
Study NCT03885219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel and S-1
Description: Nab-paclitaxel: 120 mg/m2 d1, 8, S-1:Body surface area \< 1.25 m2, 80 mg/d; Body surface area ≥ 1.25 m2 , \< 1.5 m2, 100 mg/d; Body surface area ≥1.5 m2, 120 mg/d; Bid, d1-14; repeat every 21 days.
Study NCT01316991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chewing Gum
Description: chewing gum will be provided
Study NCT01316991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No Gum
Description: no chewing gum will be provided
Study NCT00523978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Front® Cryoablation Catheter
Description: Experimental Subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci with the cryoablation catheter system.
Study NCT00523978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flecainide or Sotalol or Propafenone
Description: Flecainide 200 mg / day Propafenone 450 mg / day Propafenone-SR 650 mg / day Sotalol 240 mg / day
Study NCT01530958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CKD Registry
Description: Primary care providers (PCPs) will have access to a Chronic Kidney Disease (CKD) registry for patient care. The registry will:~* identify patients with CKD~* notify PCPs of a patients' CKD status~* provide PCP outreach with NKDEP guidelines and patient educational materials
Study NCT01530958 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CKD Registry
Description: Primary care providers (PCPs) will have access to a Chronic Kidney Disease (CKD) registry for patient care. The registry will:~* identify patients with CKD~* notify PCPs of a patients' CKD status~* provide PCP outreach with NKDEP guidelines and patient educational materials
Study NCT01530958 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ATSM + Health Coach
Description: Patients with CKD will participate in an Automated Telephone Self Management (ATSM) program, which blends automated phone calls with live targeted call-backs from a health coach. Patients will receive bi-weekly automated calls for 52 weeks in their native language, consisting of pre-recorded queries pertaining to CKD management, preventive services, and lifestyle changes. Patients will interact with the system using a touch-tone keypad; Out-of-range values or invalid responses will prompt a live call-back within 24-48 hours by a health coach.
Study NCT01530958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ATSM + Health Coach
Description: Patients with CKD will participate in an Automated Telephone Self Management (ATSM) program, which blends automated phone calls with live targeted call-backs from a health coach. Patients will receive bi-weekly automated calls for 52 weeks in their native language, consisting of pre-recorded queries pertaining to CKD management, preventive services, and lifestyle changes. Patients will interact with the system using a touch-tone keypad; Out-of-range values or invalid responses will prompt a live call-back within 24-48 hours by a health coach.
Study NCT01530958 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Primary care providers will manage their patients with CKD per usual care.~Patients will receive usual care.
Study NCT01350323 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous sample
Description: Aqueous sample (0.1ml of aqueous)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
Study NCT01350323 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous sample
Description: Aqueous sample (0.1ml)+intravitreal injection of bevacizumab (1.25mg/0.05ml)
Study NCT01350323 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous sample
Description: Aqueous sample (0.1ml)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
Study NCT01350323 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Aqueous sample
Description: Aqueous sample (0.1ml)
Study NCT03261830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Primary intervention
Study NCT03261830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: For use in Pre-operative Antibiotics arm in cases of documented allergy to primary intervention.
Study NCT03261830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo Intervention
Study NCT02850601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate
Study NCT02443584 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pharmacogenetic testing
Description: pharmacogenetic testing for anti-depressant/anti-psychotic medications
Study NCT02130531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emixustat HCl Tablet
Description: Tablet for oral administration
Study NCT02130531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Tablet
Description: Tablet for oral administration
Study NCT02850601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate
Study NCT03864978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin delayed release 400 mg tablet
Description: Rifaximin delayed release
Study NCT00809315 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment
Description: Cognitive, academic achievement, and mental health screening assessment and report.
Study NCT03864978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00809315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment
Description: Cognitive, academic achievement, and mental health screening assessment and report.
Study NCT00809315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fostering Healthy Futures (FHF)
Description: Weekly therapeutic skill groups and mentoring over a 9-month period.
Study NCT01999426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Airway clearance intervention
Description: Both respiratory and non-respiratory on-call physiotherapists provide similar airway clearance treatments, the precise components and delivery of which will vary between physiotherapists
Study NCT01999426 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Airway clearance intervention
Description: Both respiratory and non-respiratory on-call physiotherapists provide similar airway clearance treatments, the precise components and delivery of which will vary between physiotherapists
Study NCT02108288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-1085EL ophthalmic solution
Study NCT02108288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carteolol long-acting ophthalmic solution
Study NCT02108288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution
Study NCT03323164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate
Description: Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.
Study NCT03323164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine Tartrate
Description: Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.
Study NCT03953807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Intravitreal Implant
Description: Implant 700 μg
Study NCT01593917 — intervention group
Intervention type: DEVICE
Intervention: Trifecta™ Valve
Description: Aortic valve replacement with the Trifecta™ aortic bioprosthesis.
Study NCT00706355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04217903
Description: Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days
Study NCT03648619 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Semi whole-body MRI
Description: Single semi-automatic, semi whole-body MRI protocol (Dot engine)
Study NCT02661750 — intervention group
Intervention type: DRUG
Intervention: Bowel Preparation
Description: Standard 1/2 Dose: 153 g MiraLAX + 32 oz Gatorade 2 liters, 2 liters NuLYTELY, 1 liter MoviPrep, 16 oz (1 bottle) SuPREP, 10 oz (1 bottle) MagCitrate.~Standard Full Dose: 306 g MiraLAX + 64 oz Gatorade, 4 liters NuLYTELY, 2 liters MoviPrep, 32 oz (2 bottles) SuPREP, 20 oz (2 bottles) MagCitrate.~Step 1: 51 g MiraLAX\* noon the day-prior; Full dose - 51 g MiraLAX 6 PM day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 2: 1/2 dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 3: Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 4: 1/2 dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 5: Full dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.
Study NCT01123096 — intervention group
Intervention type: PROCEDURE
Intervention: Cough Stress Test
Description: A cough stress test is performed by using a catheter to introduce 300ml of sterile water into the bladder. The patient is then asked to stand and cough forcefully and the clinician will observe for urine loss.